Plain English Summary
Background and study aims
Crohn’s disease (CD) is one of the main types of inflammatory bowel disease (IBD), a name given to long-term conditions which causes inflammation (swelling) in the digestive system (gut). Although it can affect any part of the gut, it is most common at the end of the ileum (the last part of the small intestine) or the colon (the large intestine). It is characterised by different phases of disease activity, alternating between remission (when the disease is not active) and flare-ups (when the disease is active and causing symptoms). Currently, there is no cure for Crohn’s disease, and so treatments tend to be geared towards ensuring the disease remains in remission. Currently, little is known about the effects of exercise in CD; however it could have several beneficial effects such as reducing fatigue and inflammation, increasing muscle and bone strength, and improving overall quality of life. The aim of this study is to look into the effects of a high-intensity exercise programme and a moderate-intensity exercise programme on people suffering from CD.
Who can participate?
People between 16 and 65 who have mildly active or inactive Crohn’s disease.
What does the study involve?
Participants are randomly allocated to one of three groups. Those in the first group are invited to attend 3 high-intensity exercise sessions a week for 12 weeks, using an exercise bike. The sessions begin with a five-minute warm up, and then alternating one-minute bouts of hard cycling with one-minute bouts of easy cycling, for 20 minutes, before a three-minute cool down. Those in the second group are invited to attend 3 moderate-intensity exercise sessions a week for 12 weeks, using an exercise bike. The sessions begin with a five-minute warm up, and then 30 minutes of cycling at moderate intensity, before a three-minute cool down. In both groups, the resistance level (how hard it is) is increased at 4 and 8 weeks. Those in the third group do not take part in any additional exercises. At the start of the study, and then again at 13 and 26 weeks, participants complete a number of questionnaires and physical tests in order to find out if there has been any change to their health and mental well-being. At the start of the study and week 13, participants are asked to provide a stool (faeces) sample and a blood sample, so that their body’s level of inflammation can be assessed.
What are the possible benefits and risks of participating?
Potential benefits of participating include improved physical fitness and reduced fatigue which can improve general health. There are no direct risks of participating, as the exercise programmes have been found to be safe and all sessions will be closely monitored by a clinical co-investigator.
Where is the study run from?
University of East London (UK)
When is the study starting and how long is it expected to run for?
January 2016 to December 2017
Who is funding the study?
Crohn's and Colitis UK (UK)
Who is the main contact?
Dr Lindsay Bottoms
Trial website
http://www.crohnsandcolitis.org.uk/research/projects/exercise-and-ibd
Contact information
Type
Scientific
Primary contact
Dr Lindsay Bottoms
ORCID ID
http://orcid.org/0000-0003-4632-3764
Contact details
University of Hertfordshire
College Lane
Hatfield
AL10 9AB
United Kingdom
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
19920
Study information
Scientific title
A randomised controlled trial investigating the feasibility and acceptability of high-intensity interval training and moderate-intensity continuous training in adults with inactive or mildly active Crohn’s disease
Acronym
Study hypothesis
The aim of the study is to explore the feasibility, acceptability and possible benefits of high-intensity interval training and moderate-intensity continuous training on people with Crohn’s disease.
Ethics approval
London - Camden & Kings Cross Research Ethics Committee, 24/11/2015, ref: 15/NW/0813
Study design
Multi-centre randomised controlled trial
Primary study design
Interventional
Secondary study design
Randomised parallel trial
Trial setting
Other
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Topic: Gastroenterology; Subtopic: Gastroenterology; Disease: All Gastroenterology
Intervention
Participants are randomly allocated to one of three groups.
High-intensity training group: Participants will be invited to complete three exercise sessions each week for 12 consecutive weeks. All exercise will be performed on a stationary upright cycle ergometer. Each session will begin with a 5-minute warm-up of easy cycling. The main body of each session will involve ten, 1-minute bouts of hard cycling, interspersed with 1-minute bouts of easy cycling. The session will end with a 3-minute cool-down of easy cycling. The resistance level on the cycle ergometers will be progressed after 4 and 8 weeks of training.
Moderate-intensity training group: Participants will be invited to complete three exercise sessions each week for 12 consecutive weeks. All exercise will be performed on a stationary upright cycle ergometer. Each session will begin with a 5-minute warm-up of easy cycling. The main body of each session will involve 30 minutes of cycling at a moderate intensity. The session will end with a 3-minute cool-down of easy cycling. The resistance level on the cycle ergometers will be progressed after 4 and 8 weeks of training.
Control group: Participants continue as normal, and do not undertake any additional activity.
All exercise sessions will be supervised in a university sports science laboratory or a hospital rehabilitation facility. Data will be collected in order to assess the feasibility of conducting a future large-scale study of exercise training in CD. In addition, possible benefits of the exercise programmes to be explored include reduced inflammation (measured using blood and stool samples), increased fitness (assessed using a cycling exercise test), and improved fatigue levels, mental health and quality of life (using standardised questionnaires). Participants will be assessed at 13 and 26 weeks after joining the study.
Intervention type
Other
Phase
Drug names
Primary outcome measure
1. Recruitment rates are calculated when the recruitment period is complete
2. Intervention adherence rates are calculated when intervention delivery period is complete
3. Missing data rates are calculated when follow-up is complete
4. Retention rates are calculated when follow-up is complete
Secondary outcome measures
1. Blood markers of inflammation (e.g. IL-6, CRP) are measured at baseline and 13 week in all participants, and week 7 in exercise group participants
2. Body mass is determined at baseline and 13 weeks
3. Cardiorespiratory fitness (ventilatory threshold and peak oxygen uptake) is determined at baseline and 13 weeks
4. Disease symptoms are measured using the Crohn's Disease Activity Index at baseline and 13 weeks
5. Health status is measured using the EuroQol EQ-5D-5L questionnaire at baseline, 13 and 26 weeks
6. Bowel inflammation is dertermined by measuring faecal calprotectin at baseline and 13 weeks
7. Anxiety and depression are measured using the Hospital Anxiety and Depression Scale at baseline, 13 and 26 weeks
8. Fatigue is measured using the Inflammatory Bowel Disease Fatigue Scale at baseline, 13 and 26 weeks
9. Quality of life is measured using the Inflammatory Bowel Disease Quality of Life Questionnaire at baseline, 13 and 26 weeks
10. Physical activity is measured using the International Physical Activity Questionnaire at baseline, 13 and 26 weeks
11. Resting blood pressure is measured at baseline and 13 weeks
12. Resting heart rate is measured at baseline and 13 weeks
13. Waist circumference is measured at baseline and 13 weeks
Overall trial start date
01/01/2016
Overall trial end date
31/12/2017
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. Aged between 16 and 65 years
2. Clinical diagnosis of CD for at least 4 weeks before the screening visit
3. Mildly active (150 to 219 on Crohn’s Disease Activity Index [CDAI]) or inactive (<150 on CDAI) CD assessed no greater than 4 weeks before the screening visit
4. Faecal calprotectin <250 mcg/g recorded no greater than 4 weeks before the screening visit
5. Stable medications for at least 4 weeks before the screening visit
6. Able to provide written informed consent and complete the study questionnaires
7. Able to travel to the research centre for assessment visits and exercise sessions
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
Planned Sample Size: 45; UK Sample Size: 45
Participant exclusion criteria
1.Absolute contraindications to exercise testing and training as defined by the American College of Sports Medicine
2. Coexistent serious autoimmune disease such as rheumatoid arthritis or systemic sclerosis
3. Planned major surgery within the first 3 months after randomisation
4. Pregnant
5. Female planning pregnancy within the first 3 months after randomisation
6. Poor tolerability of venepuncture
7. Lack of adequate venous access for required blood sampling
8. Current participation in more than 90 min/week of purposeful exercise, such as jogging or swimming
9. Participation in another clinical trial for with concurrent participation is deemed inappropriate
Recruitment start date
01/04/2016
Recruitment end date
31/03/2017
Locations
Countries of recruitment
United Kingdom
Trial participating centre
University of East London
University Way
London
E16 2RD
United Kingdom
Funders
Funder type
Charity
Funder name
Crohn's and Colitis UK
Alternative name(s)
Crohn's & Colitis UK
Funding Body Type
private sector organisation
Funding Body Subtype
Associations and societies (private and public)
Location
United Kingdom
Results and Publications
Publication and dissemination plan
The dissemination strategy for this research will be to inform a wide range of local, national and international audiences about the results and conclusions. It must, however, be remembered as part of this strategy that the current project is preliminary work aimed at informing a subsequent definitive clinical trial.
Health professionals:
We aim to publish our research in journals that cover the relevant medical specialities and with preference for those that deposit publications in open access databases to increase free dissemination. In addition, we aim to present this research at appropriate national and international conferences.
Users:
From this perspective, we aim in the first instance to collaborate with our patient's representatives and local experts in the patient and public involvement to best facilitate user dissemination. We plan to write a specific news piece that will be forwarded to appropriate groups and organisations.
Service managers:
As an exploratory study, it is unlikely that results from this study will directly influence commissioning processes in the short term. Moreover, we will engage with appropriate primary and secondary care groups to discuss support for our proposed definitive study leading on from this research.
Intention to publish date
30/06/2018
Participant level data
Available on request
Basic results (scientific)
Publication list
2017 protocol in: https://www.ncbi.nlm.nih.gov/pubmed/28373911